C9orf72 and amyotrophic lateral sclerosis: A placebo-controlled, phase 2 study is ongoing to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AL-001 in patients with C9orf72-associated ALS (Alector, 2021).